ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚÀÇ ¾çÀüÀÚ¹æÃâ ´ÜÃþÃÔ¿µ¿¡¼ °ñ¼ö ´ë»çÈ°¼ºµµÀÇ Ç×¾ÏÈÇпä
Association between Bone Marrow Hypermetabolism on 18F-Fluorodeoxyglucose
°áÇÙ¹×È£Èí±âÁúȯ 2009³â 66±Ç 1È£ p.20 ~ p.26
¼³ÈñÀ±(Seol Hee-Yun) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
±è¼ºÀå(Kim Seong-Jang) - ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ ÇÙÀÇÇб³½Ç
¸ñÁ¤ÇÏ(Mok Jeong-Ha) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
±èÁöÀº(Kim Ji-Eun) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
±è±â¿í(Kim Ki-Uk) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
¹ÚÇý°æ(Park Hye-Kyung) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
±èÀ±¼º(Kim Yun-Seong) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
À̹αâ(Lee Min-Ki) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
¹Ú¼ø±Ô(Park Soon-Kew) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
À±¼ºÈÆ(Yoon Seong-Hoon) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
Abstract
¿¬±¸¹è°æ: ¾çÀüÀÚ¹æÃâ ´ÜÃþÃÔ¿µÀº ÃÖ±Ù Æó¾ÏÀÇ Áø´Ü°ú º´±â °áÁ¤¿¡ ³Î¸® »ç¿ëµÈ´Ù. º» ¿¬±¸¿¡¼´Â ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚ¿¡¼ ¾çÀüÀÚ¹æÃâ ´ÜÃþÃÔ¿µ¿¡¼ÀÇ °ñ¼ö ´ë»çÈ°¼ºµµÀÇ Áõ°¡°¡ Ç×¾ÏÈÇпä¹ý¿¡ ´ëÇÑ ¹ÝÀÀ°ú °ü·Ã¼ºÀÌ ÀÖ´ÂÁö ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
¹æ ¹ý: Á¶Á÷ÇÐÀûÀ¸·Î ºñ¼Ò¼¼Æ÷Æó¾ÏÀ¸·Î Áø´Ü ¹ÞÀº ȯÀÚ Áß¿¡ ¾çÀüÀÚ ¹æÃâ ´ÜÃþÃÔ¿µÀ» ½ÃÇàÇÑ ÈÄ ÀÏÂ÷ Ç×¾ÏÈÇпä¹ýÀ» ½ÃÇà ¹ÞÀº ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿´´Ù. ´ë»ó±ºÀÇ ¾çÀüÀÚ ¹æÃâ ´ÜÃþÃÔ¿µ»ó °ñ¼ö ´ë»çÈ°¼ºµµ´Â ¿äÃß 1, 2, 3¹øÀÇ FDG ¼·Ã븦 ÃøÁ¤ÇÏ¿© Æò°¡ÇÏ¿´°í, Ç×¾ÏÈÇпä¹ý¿¡ ´ëÇÑ ¹ÝÀÀÀº Response Evaluation Criteria in Solid Tumors(RECIST)¸¦ ÀÌ¿ëÇÏ¿© Æò°¡ÇÏ¿´´Ù.
°á °ú: ÃÑ 59¸íÀÇ È¯ÀÚ°¡ Æ÷ÇԵǾú´Ù. ´ë»ó±ºÀ» ¾çÀüÀÚ¹æÃâ ´ÜÃþÃÔ¿µ»ó °ñ¼öÀÇ SUV°¡ 1.37 ÀÌ»óÀÎ ±º(21¸í,35.6%)°ú ¹Ì¸¸ÀÎ ±º(38¸í, 64.4%)À¸·Î ³ª´©¾ú°í, °ñ¼öÀÇSUV¿Í °£ÀÇ SUVÀÇ ºñ°¡ 0.73 ÀÌ»óÀÎ ±º(22¸í, 37.3%)°ú ¹Ì¸¸ÀÎ ±º(37¸í, 62.7%)·Î ³ª´©¾î ÀÏÂ÷ Ç×¾ÏÈÇпä¹ý¿¡ ´ëÇÑ ¹ÝÀÀÀ» ºñ±³ÇÏ¿´´Ù. °ñ¼öÀÇ SUV¿Í °ñ¼öÀÇ SUV¿Í °£ÀÇ SUVÀÇ ºñ´Â ÀÏÂ÷ Ç×¾ÏÈÇпä¹ý¿¡ ´ëÇÑ ¹ÝÀÀ°ú Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù(p=0.142, 0.978).
°á ·Ð: ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚ¿¡¼ ¾çÀüÀÚ¹æÃâ ´ÜÃþÃÔ¿µ¿¡¼ ³ªÅ¸³ °ñ¼ö ´ë»çÈ°¼ºµµ´Â Ç×¾ÏÈÇпä¹ý¿¡ ´ëÇÑ ¹ÝÀÀ°ú °ü·Ã¼ºÀÌ ¾ø¾ú´Ù.
Background: 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) is widely used for the diagnosis and staging of non-small cell lung cancer (NSCLC). The aim of this study is to determine whether the bone marrow hypermetabolism seen on FDG-PET predicts a response to chemotherapy in patients with NSCLC.
Methods: We evaluated the patients with advanced NSCLC and who were treated with combination chemotherapy. For determination of the standardized uptake value (SUV) of the bone marrow (BM SUV) on FDG-PET, regions of interest (ROIs) were manually drawn over the lumbar vertebrae (L1, 2, 3). ROIs were also drawn on a homogenous transaxial slice of the liver to obtain the bone marrow/ liver SUV ratio (BM/L SUV ratio). The response to chemotherapy was
evaluated according to the Response Evaluation Criteria in Solid Tumor (RECIST) criteria after three cycles of
chemotherapy.
Results: Fifty-nine NSCLC patients were included in the study. Multivariate analysis was performed using a logistic
regression model. The BM SUV and the BM/L SUV ratio on FDG-PET were not associated with a response to
chemotherapy in NSCLC patients (p=0.142 and 0.978, respectively).
Conclusion: The bone marrow hypermetabolism seen on FDG-PET can not predict a response to chemotherapy in NSCLC patients.
Å°¿öµå
Non-small cell lung cancer, Bone marrow, 18F-Fluorodeoxyglucose positron emission tomography
KMID :
0383820090660010020
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚ¿¡¼ ¾çÀüÀÚ¹æÃâ ´ÜÃþÃÔ¿µ¿¡¼ ³ªÅ¸³ °ñ¼ö ´ë»çÈ°¼ºµµ´Â Ç×¾ÏÈÇпä¹ý¿¡ ´ëÇÑ ¹ÝÀÀ°ú °ü·Ã¼ºÀÌ ¾ø¾ú´Ù.